| Drug General Information |
| Drug ID |
D0M2AN
|
| Former ID |
DIB000670
|
| Drug Name |
AD-412
|
| Synonyms |
JAK3 inhibitor (autoimmune disease/transplant rejection), INSERM
|
| Indication |
Autoimmune diabetes [ICD10:E08-E13]
|
Investigative |
[1]
|
|---|
| Company |
INSERM
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
n1(cc(c2c1cccc2)CCC(=O)Nc1ccncc1)Cc1ccc(Cl)cc1
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Measles
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
Interleukin signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-2 signaling
|
|
RAF/MAP kinase cascade
|
|
Interleukin receptor SHC signaling
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
Interleukin-2 signaling
|
|
Interleukin-7 signaling
|
|
Oncostatin M Signaling Pathway
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). |
|---|
